Cell and gene therapy costs rising slowly but could reshape employer health plans: Research

A new study out of the United States finds that while cell and gene therapies remain rare in employer health plans, their use is climbing — and even a single claim can deliver a major financial hit to smaller organizations. The Employee Benefit Research Institute released research Feb. 19 analyzing ...